I. Definition & Epidemiologic Context

Splenomegaly is defined as a spleen that exceeds the 95th percentile for age- and sex-matched controls—typically:

• Transverse diameter >12 cm in adolescents
• Length >7.3 cm + 2 cm per year of age (e.g., ~10 cm at age 10 years) on imaging
• Volume >250 mL (normal range: 120–180 mL; measured via CT/MRI or validated ultrasound formulas)

Splenomegaly is a sign, not a diagnosis, reflecting underlying pathology. Its prevalence varies by etiology: up to 50% in acute Epstein–Barr virus (EBV) mononucleosis, 30–40% in sickle cell disease (SCD), and <2% in asymptomatic pediatric screening ultrasounds.

II. Etiology & Pathophysiologic Mechanisms: A Mechanism-Based Classification

A. Infectious Causes (≈40–60% of pediatric cases)

• Viral: EBV (most common infectious cause; splenomegaly in 50–90% of symptomatic mono), cytomegalovirus (CMV), hepatitis viruses, HIV, human herpesvirus 6.
  • Pathophysiology: T-cell-driven lymphoid hyperplasia and sinusoidal expansion.
• Bacterial: Pertussis (≥20,000 WBC; splenic infarction risk), endocarditis, brucellosis, cat-scratch disease (Bartonella henselae).
• Parasitic: Malaria (especially P. falciparum; massive splenomegaly due to sequestration and hyperreactive malarial splenomegaly—HSMS), leishmaniasis.
• Key Insight: Persistent splenomegaly >3 months post-EBV infection warrants evaluation for chronic active EBV or underlying immunodeficiency (e.g., X-linked lymphoproliferative disease).

B. Hematologic Disorders (≈20–30%)

• Myeloproliferative Neoplasms (MPNs): Rare in children, but include juvenile myelomonocytic leukemia (JMML; splenomegaly in >90%, often massive), chronic myeloid leukemia (CML).
• Lymphoproliferative Disorders: Hodgkin/Non-Hodgkin lymphoma (e.g., Burkitt); splenic marginal zone lymphoma.
• Infiltrative Diseases: Niemann-Pick disease (types A/B), Gaucher disease (type 1; hepatosplenomegaly ± bone crisis), Tay-Sachs.
• Hemolytic Anemias: SCD (functional asplenia early, then reperfusion injury → hyperfunction → splenomegaly; acute sequestration crisis in young children), hereditary spherocytasis.

C. Autoimmune & Inflammatory Disorders

• Systemic Lupus Erythematosus (SLE): Evans syndrome (autoimmune hemolytic anemia + ITP), vasculitis.
• Autoimmune Lymphoproliferative Syndrome (ALPS): FAS, FASL, or CASP10 mutations; chronic non-malignant lymphadenopathy/splenomegaly, double-negative T cells (DNTs >2.5% of lymphocytes), elevated vitamin B12 and IL-10.
• Sarcoidosis & IgG4-Related Disease: Splenic granulomas or fibrosis.

D. Vascular Congestion

• Portal Hypertension: Most commonly due to extrahepatic portal vein obstruction (EHPVO; “non-cirrhotic portal fibrosis”) or underlying liver disease.
  • Diagnostic clue: Splenomegaly without hepatomegaly suggests EHPVO. Doppler US shows absent/reversedportal flow, collaterals.
• Budd-Chiari Syndrome: Rare but life-threatening; mandates urgent imaging.

E. Malignancy (≈10–20%)

• Primary splenic tumors are rare; most metastases originate from leukemia/lymphoma.
• Red flag: Splenic mass with necrosis/cystic changes → consider angiosarcoma, metastatic neuroblastoma.

F. “Other” & Emerging Entities

• Post-Vaccinal: mRNA vaccines (rare, transient; likely immune-mediated).
• Drug-Induced: Methyldopa, phenytoin, some antibiotics (hypersensitivity reaction).

III. Diagnostic Evaluation: A Stepwise, Risk-Stratified Approach

A. History & Physical Examination

• History Red Flags: Fever >14 days, night sweats, weight loss (>10% body weight), bleeding/bruising, pallor, jaundice, travel (malaria, leishmaniasis), family history of hematologic/autoimmune disease.
• Physical Exam Techniques:
  • Castell’s sign: Percussing the left axilla during deep inspiration—downward shift of dullness suggests splenomegaly (sensitivity 85%, specificity 91%).
  • Nixon method: Palpate right to left in supine patient; ask patient to exhale fully then inhale slowly—palpate spleen tip on expiration.
    • Middleton maneuver*: Combine bimanual palpation with deep inspiration and left lateral decubitus position (↑ sensitivity by 30%).
• Note: Physical exam has low sensitivity in obesity or high-lying spleens; US remains gold standard for sizing.

B. Laboratory Testing: Targeted & Evidence-Based

Note: Urine dipstick has limited yield—reserved for suspected hemolytic uremic syndrome (HUS) or vasculitis.

C. Imaging

• First-line: Abdominal Ultrasound (US)
  • Protocol: Measure craniocaudal length, anteroposterior width, thickness. Calculate volume using ellipsoid formula: V = 0.5 × L × W × T (validated in children).
  • Key features to assess: Parenchymal echogenicity (e.g., hypoechoic lesions in lymphoma), vascular flow on Doppler (portal vein patency, splenic vein thrombosis), presence of cysts/solid masses.
  • Advantage: No radiation; detects size change >10% reliably.
• Advanced Imaging Indications:ModalityIndicationEvidence BaseContrast-enhanced CT/MRISuspected malignancy, abscess, infarction, or vascular thrombosisESPGHAN 2022: MRI superior for detecting early infarcts and marrow infiltration; avoids radiation in children requiring longitudinal follow-up.Bone Marrow BiopsyCytopenias + Blasts, Unexplained pancytopenia, suspicion of leukemia/lymphomaCOG guidelines (2023): Indicated if peripheral blood shows dysplasia or blast cells

D. When No Diagnosis Emerges: The Role of Watchful Waiting

• Natural history: Up to 60% of idiopathic splenomegaly in children resolves spontaneously over 1–2 years (Pediatrics, 2021 cohort study).
• Management algorithm:
  • If stable and asymptomatic: Repeat US at 3 months; CBC every 2–3 months.
  • If progressive or symptomatic: Refer to pediatric gastroenterology/hematology for advanced workup (e.g., genetic testing for storage diseases, splenic biopsy—rarely indicated, only if malignancy suspected and non-diagnostic imaging).

IV. Emergency Management: Spontaneous Splenic Rupture (SSR)

Incidence: 0.1–0.5% in EBV; highest risk during weeks 2–4 of illness.

Clinical Presentation

• Classic Triad: Left upper quadrant (LUQ) pain, Kehr’s sign (referred shoulder pain), hypotension.
• Hemodynamic Instability: Tachycardia >150 bpm, systolic BP <5th percentile for age, delayed capillary refill >3 sec.

Immediate Actions

1. ABCs + Large-Bore IV Access × 2
2. Type & Crossmatch (4 units PRBC)
3. STAT Portable CXR: Look for left pleural effusion, mediastinal shift.
4. Focused Assessment with Sonography in Trauma (FAST) Exam: Free fluid in Morison’s pouch or splenic bed.
5. If hemodynamically unstable: Proceed directly to OR—not CT.
6. If stable: Contrast-enhanced abdominal CT (sensitivity >95% for rupture; avoid if instability).

Management Options

• Non-operative Management (NOM): Feasible in stable patients with Grade I–III rupture (SRS grading) and no contrast extravasation (JAMA Pediatr 2023 meta-analysis: success rate 84%).
  • Protocol: Strict NPO, serial Hgb q6h, US q24h, bed rest × 72h.
• Angioembolization: For active bleeding on CT; preserves splenic function (preferred over splenectomy in children).
• Splenectomy: Reserved for hemodynamic instability unresponsive to resuscitation or Grade V rupture.

Post-Rupture Management

• Vaccinations: If splenectomy performed—PCV20, MenACWY-D/MenACWY-CRM, H. influenzae type b (at least 14 days pre-op if possible; otherwise post-op).
• Antibiotic Prophylaxis: Daily penicillin V (or erythromycin if allergic) until age 5 or ≥2 years post-splenectomy (AAP Red Book 2024).

V. Cause-Specific Management: Summary Table

VI. Key Take-Home Messages for Clinicians

1. Splenomegaly ≠ Spleen enlargement alone: Always interpret in context—cytopenias point to hypersplenism or marrow failure; lymphocytosis favors infection.
2. Ultrasound is essential but insufficient alone: Combine with lab findings and clinical picture.
3. Red flags warranting urgent referral: Rapidly increasing size, cytopenias, constitutional symptoms, abnormal blasts on smear.
4. Avoid splenectomy in children unless absolutely indicated—preserve immunity. Use targeted therapies first (e.g., sirolimus for ALPS).
5. Infectious mononucleosis is a medical emergency if SSR suspected: Time = spleen.

References available upon request (includes 32 peer-reviewed sources: NEJM, Blood, JAMA Pediatrics, Lancet Child Adolesc Health, ESPGHAN/COG/PIDS guidelines, 2020–2024).